High-Risk Clinic for Melanoma Surveillance Is Scalable
TUESDAY, March 23, 2021 -- A structured surveillance program for high-risk melanoma patients can be scaled and successfully replicated even in a primary care skin cancer clinic, according to a study published online March 17 in JAMA Dermatology.
Pascale Guitera, M.D., Ph.D., from the Melanoma Institute Australia at the University of Sydney, and colleagues examined the longer-term sustainability and expansion of a melanoma surveillance program for high-risk patients (full-body examinations every six months aided by total-body photography [TBP] and sequential digital dermoscopy imaging) to numerous practices, including a primary care skin cancer clinic setting. The analysis included 593 patients assessed from 2012 to 2018 at three dermatology clinics and one primary care skin cancer clinic.
The researchers found 1,513 lesions were excised during follow-up, including 171 primary melanomas, and excision ratios were similar across the four centers. In the first two years, the risk for developing a new melanoma was 9 percent annually, which increased with time, particularly for those with multiple primary melanomas. The seven thicker melanomas (>1 mm Breslow thickness; 4.1 percent of melanomas) were mostly desmoplastic or nodular (four of seven), self-detected (two of seven), or clinician detected without the aid of TBP (three of seven). New melanomas (171) were most likely to be detected by a clinician with the aid of TBP (31.6 percent) followed by digital dermoscopy monitoring (29.2 percent).
"The findings of this cohort study suggest that the structured surveillance program may be implemented on a larger scale, including at primary care skin cancer clinics, with consistent and sustainable benefits observed," the authors write.
One author disclosed financial ties to a medical technology company and one disclosed ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: March 2021
Read this next
FRIDAY, April 16, 2021 -- Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more...
MONDAY, April 12, 2021 -- A tanning bed ban for U.S. minors would be cost-effective, according to a study published online April 12 in Cancer. Antoine Eskander, M.D., from the...
MONDAY, April 12, 2021 -- Higher exposure to thiazides is associated with increased rates of incident keratinocyte carcinoma and melanoma among older adults, according to a study...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.